Literature DB >> 9973032

Nonexercise stress transthoracic echocardiography: transesophageal atrial pacing versus dobutamine stress.

C Y Lee1, P A Pellikka, R B McCully, D W Mahoney, J B Seward.   

Abstract

OBJECTIVES: To compare transesophageal atrial pacing stress echocardiography with dobutamine stress echocardiography for feasibility, safety, duration, patient acceptance and concordance in inducing wall motion abnormalities.
BACKGROUND: Transesophageal atrial pacing is an effective method of increasing heart rate and has been used in the assessment of coronary artery disease.
METHODS: Both tests were performed in sequence on the same patients in random order. Transesophageal atrial pacing stress echocardiography began at a heart rate of 10 beats/min above the baseline value and was increased by 20 beats/min every two min until 85% of the age-predicted maximum heart rate or another end point was reached. Dobutamine echocardiography was performed using three-min stages and a maximum dose of 40 microg/kg per min. Atropine (total dose < or =2 mg) was administered at the start of the 40 microg/kg per min stage if needed to augment heart rate or during pacing if Wenckebach heart block occurred.
RESULTS: Transesophageal atrial pacing stress echocardiography was feasible in 100 of 104 patients (96%); the duration (8.6+/-3.6 min) was significantly shorter than that of dobutamine stress echocardiography (15.1+/-3.9 min) (p = 0.0001). With transesophageal atrial pacing stress echocardiography, the recovery period was shorter, symptoms and dysrhythmias were fewer, hypertension and hypotension were less common and target heart rate was more frequently achieved. No complications occurred with either test. Patient acceptance was satisfactory. Agreement between results of both tests was good for segmental wall motion scoring with a 16-segment model, scores 1 to 5 (kappa: rest, 0.79; peak, 0.57) and test interpretation (normal, ischemia, infarction or resting wall motion abnormality with ischemia) (kappa: 0.77).
CONCLUSIONS: Transesophageal atrial pacing stress echocardiography is a feasible, well-tolerated alternative to dobutamine stress echocardiography. It can be performed rapidly and shows good agreement with dobutamine stress echocardiography in the induction of myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973032     DOI: 10.1016/s0735-1097(98)00599-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Stress echocardiography in the diagnosis of coronary artery disease.

Authors:  W Mazur; S F Nagueh
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

2.  Detection of coronary stenoses by stress echocardiography using a previously implanted pacemaker for ventricular pacing: preliminary report of a new method.

Authors:  D Benchimol; M Mazanof; B Dubroca; H Benchimol; V Bernard; T Couffinhal; J F Dartigues; R Roudaut; X Pillois; J Bonnet
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

3.  Transoesophageal atrial pacing combined with transthoracic two dimensional echocardiography: experience in patients operated on with arterial switch operation for transposition of the great arteries.

Authors:  E De Caro; G P Ussia; M Marasini; G Pongiglione
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

Review 4.  Stress echocardiography for the detection and assessment of coronary artery disease.

Authors:  Nowell M Fine; Patricia A Pellikka
Journal:  J Nucl Cardiol       Date:  2011-05       Impact factor: 5.952

5.  Association of aortic valve sclerosis and coronary artery disease in patients with severe nonischemic mitral regurgitation.

Authors:  Andrea Rossi; Gerald Bertagnolli; Mariantonietta Cicoira; Giorgio Golia; Luisa Zanolla; Francesco Santini; Claudio Cemin; Gabriele Ferrario; Piero Zardini
Journal:  Clin Cardiol       Date:  2003-12       Impact factor: 2.882

Review 6.  Pacing stress echocardiography.

Authors:  Suzana Gligorova; Marco Agrusta
Journal:  Cardiovasc Ultrasound       Date:  2005-12-09       Impact factor: 2.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.